Post-pandemic healthcare trends will turn, says SEB's new biotech portfolio lead

Two of SEB's healthcare funds will switch from a quant to a fundamental approach as the funds have been left behind by their benchmarks. The strategy revamp aims to better utilize investment opportunities in the sector.
Photo: Photo: Pexels: Martin Lopez.
Photo: Photo: Pexels: Martin Lopez.

Some of the prevailing trends in healthcare and biotech funds during Covid-19 pandemic will reverse as the economy opens up post-pandemic, says Angelica Fatouros, portfolio manager of healthcare and biotechnology funds at SEB Investment Management.

Already a subscriber?Log in here

Read the whole article

Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

With your free trial you get:

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
  • Must be at least 8 characters, including three of: Uppercase, lowercase, numbers, symbols
    Must contain at least 2 characters
    Must contain at least 2 characters

    Get full access for you and your coworkers

    Start a free company trial today

    Share article

    Sign up for our newsletter

    Stay ahead of development by receiving our newsletter on the latest sector knowledge.

    Newsletter terms

    Front page now

    Further reading